This link will take you to a non-ViiV Healthcare website. ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third-parties.
Assessing the efficacy and tolerability of DTG▼+3TC in HIV-1 viral suppressed patients: ANRS 167 Lamidol study1
Author : Charpentier C et al.
Added On : 15/03/2019
Tags : Dolutegravir
Lamidol is a non comparative, open-label, single-arm, multicentre trial with 2 phases.
The objective was to assess the efficacy and tolerability of DTG+3TC in HIV-1 viral suppressed patients.
The primary endpoint was the proportion of patients with treatment success* at week 48. The 97% (101/104) of patient maintained viral suppression up to week 48.
Between Week 0 and Week 48, no change was observed in plasma residual viremia level or in HIV cellular reservoir size with stable plasma DTG Cmin.1
Find more at CROI 2019 website
* Treatment success = not experiencing treatment failure defined as: having changed or stopped assigned treatment; being lost to follow-up; having VF (confirmed HIV-1 RNA >50 c/mL)
PM-GB-DLT-WCNT-190001 - March 2019
© 2020 ViiV Healthcare group of companies or its licensor. All rights reserved.
Trademarks are owned by or licensed to the ViiV Healthcare group of companies.
ViiV Healthcare UK Limited Registered in England Company number: 06990358 Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS
PM-GB-HVX-WCNT-200003 | March 2020